The primary objective for designing drugs that selectively inhibit COX – 2 is to (a) Decrease the risk of nephrotoxicity (b) Improve anti-inflammatory effectiveness (c) Lower the risk of gastrointestinal toxicity (d) Reduce the cost of treatment of rheumatoid arthritis (e) Selectively decrease thromboxane A2 without effects on other eicosanoids